Redeye comments on Freemelt ahead of its Q2 results.
Solid order bookings given a cautious market The Q2 report showed lower sales than we expected, as w...
Redeye provides an initial comment on the Q2 2025 report from Serstech.
Q2'25 impressions Nilörn reports Q2'25 sales of SEK 237m (-3% vs.
Oriola More cautious stance on Wholesale profitability Oriola reports its Q2 results on July 18th.
Adjusted for currency effects, Enea’s net sales of SEK234.
Q2'25 report Q2 was a bit softer than expected with respect to both sales and profitability.
Redeye updates its estimates and valuation after Indutrade’s Q2 2025 report.
Redeye comments on Cantargia’s license deal with Otsaka Pharmaceutical, which is transformative for ...
Redeye provides an update following Episurf Medical’s Q2 2025 report, where net sales came in below ...
Consti’s Q2/2025 figures are due on Friday, July 18.
Better Norway offset by losses in Denmark Coor managed to turn both organic sales and EBITA growth p...
Redeye takes a more cautious approach toward the long-term prospects in Fiber Solutions, leading to ...
Ahead of Taaleri's Q2 2025 report on 13 August, we revise our estimates and slightly modify the comp...
Redeye provides an update following Iconovo’s Q2 report.
